{"id":"furfenorex","rwe":[],"tags":[{"label":"furfenorex","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"furfurylmethylamphetamine","offLabel":[],"synonyms":["furfurylmethylamphetamine","DL-Furfenorex","furfenorex"],"timeline":[],"approvals":[],"brandName":"Furfurylmethylamphetamine","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"furfenorex","explanation":"Imagine your brain is a busy city with many messengers (neurotransmitters) carrying important information. Furfenorex helps keep these messengers in the city longer, allowing them to have a greater impact on the brain's functions.","oneSentence":"Furfenorex is believed to work by inhibiting the reuptake of certain neurotransmitters in the brain.","technicalDetail":"Furfenorex is thought to act as a norepinephrine-dopamine reuptake inhibitor (NDRI), increasing the levels of these neurotransmitters in the synaptic cleft by blocking their reabsorption into the presynaptic neuron."},"commercial":{"revenueYear":2025,"annualRevenue":172,"revenueSource":"Teva 2026-02-03 (verified from SEC filing)","revenueCurrency":"USD","revenueConfidence":"high"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3752","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FURFENOREX","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:37:47.658292","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:50:28.324008+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"furfenorex","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"X83CZ0Y5TF","CHEBI":"CHEBI:134942","INN_ID":"2132","UMLSCUI":"C0060861","ChEMBL_ID":"CHEMBL2107558","PUBCHEM_CID":"26762","SNOMEDCT_US":"96243006","SECONDARY_CAS_RN":"3776-93-0","MESH_SUPPLEMENTAL_RECORD_UI":"C048537"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":11,"therapeuticAreas":["Neuroscience"],"_revenueScrapedAt":"2026-03-31 14:09:35.487336+00","biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Furfurylmethylamphetamine, also known as Furfenorex, is a small molecule drug of the furfenorex class. Its original development and current ownership are unknown. Furfenorex's target and approved indications are also unknown, and it has not been approved by the FDA. The commercial status of Furfenorex is unclear, and key safety considerations are unavailable. Further research is needed to understand this compound's pharmacology and clinical applications.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:50:28.324008+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}